Menu
  • Join
  • Login
  • Contact
 

FIP Development Goal 19: Patient safety

 

 FIP Development Goal 19 Workforce Element


FIP Development Goal 19 [w]

 

                                                                                                                                                            

Globally, we will have:

Workforce and education strategies linked to patient safety mechanism and reducing medication-related harm in practice. 

Mechanisms

  • Ensure academic capacity (FIP Development Goal 1 [w]) to deliver education and training to enhance patient safety mechanisms.

  • Incorporate patient safety and medication-related harm reduction skills in early career training strategy (FIP Development Goal 2 [w]) and continuing professional development strategies (FIP Development Goal 9 [w]).  

  • Utilise advanced and specialist development systems and frameworks (FIP Development Goal 4 [w]) to develop patient safety as an advanced or specialist area for the workforce, in addition to being embedded within leadership development programmes (FIP Development Goal 6 [w]).

  • Incorporate patient safety and medication-related harm reduction in competencies and skills in competency development frameworks for pharmacy (FIP Development Goal 5 [w]).


 

FIP Development Goal 19 Practice Element


FIP Development Goal 19 [p]

 

                                                                                                                                                                                          

Globally, we will have:

Patient safety mechanisms linked to reducing medication-related harm, quality assurance processes and legislation & regulations.

Mechanisms

  • Advocate for both safer medication management systems and a culture of patient safety in health care organisations.

  • Encourage all health care professionals and other key stakeholders, including patients and their caregivers, managers, policy makers, and educators to consider designing/optimising services collaboratively to improve patient safety.

  • In collaboration with health care professionals, health care organisations, patient/consumer organisations and researchers, develop, implement and monitor indicators and tools to proactively measure patient or consumer safety in practice; the outcomes of which can be used to promote and monitor the development of a safety culture.

  • Initiate and support ongoing programmes to educate the public about the safe use of medications and the roles of pharmacists in this context.

  • Develop, implement, promote, monitor and review medication safety policies, procedures and outcomes in hospital, primary care, community and residential care facilities and other relevant facilities to prevent patient safety incidents and improve patient outcomes

  • Ensure systems are in place for the supply of medications in times of shortages and for access to medications by patients most in need. Develop strategies to combat substandard and falsified medicines.


 

FIP Development Goal 19 Science Element 


FIP Development Goal 19 [s]

 

                                                                                          

Globally, we will have:

Safety in the development and use of medicines is promoted through the advancement of drug safety science.


Mechanisms

  • Support development of a globally harmonised approach to medicines safety monitoring with a science-based judgment of risk assessment and risk mitigation.



Find out more about the 21 FIP Development Goals for transforming global pharmacy here.
Last update 16 September 2020

FIP Congresses